Mangalam Drugs and Organics Ratios

Mangalam Drugs and Organics Ltd Ratios

The Mangalam Drugs and Organics Ltd Ratios page provides a complete fundamental analysis of Mangalam Drugs and Organics Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Mangalam Drugs and Organics Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Mangalam Drugs and Organics Ltd (NSE: MANGALAM, BSE: 532637) is currently trading at ₹31.89, with a market capitalization of ₹525.02M. As a major player in the Health technology sector and Pharmaceuticals: major industry, Mangalam Drugs and Organics Ltd remains a key stock for fundamental analysis using Mangalam Drugs and Organics Ltd Ratios.

Mangalam Drugs and Organics Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Mangalam Drugs and Organics Ltd P/E ratio currently stands at 17.48, making it one of the most tracked metrics in Mangalam Drugs and Organics Ltd Ratios.

Historically, the Mangalam Drugs and Organics Ltd P/E ratio has shown strong fluctuations:

• 2024: 17.48
• 2023: 0
• 2022: 121.95
• 2021: 8.28
• 2020: 5.62

The rising Mangalam Drugs and Organics Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Mangalam Drugs and Organics Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.79.

Historical P/B trend:

• 2024: 0.79
• 2023: 1.08
• 2022: 1.02
• 2021: 1.08

Mangalam Drugs and Organics Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Mangalam Drugs and Organics Ltd P/S ratio currently stands at 0.37, an important part of Mangalam Drugs and Organics Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 0.37
• 2023: 0.40
• 2022: 0.42
• 2021: 0.36

A stable or declining Mangalam Drugs and Organics Ltd P/S ratio indicates cautious market sentiment.

Mangalam Drugs and Organics Ltd Price to Cash Flow Ratio (P/CF)

The Mangalam Drugs and Organics Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 4.26.

Historical Mangalam Drugs and Organics Ltd Price to Cash Flow Ratio:

• 2024: 4.26
• 2023: 0
• 2022: 6.61
• 2021: 12.31
• 2020: 9.36

The rising Mangalam Drugs and Organics Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Mangalam Drugs and Organics Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Mangalam Drugs and Organics Ltd EV currently stands at ₹2.11B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 2.11B
• 2023: 2.52B
• 2022: 2.41B
• 2021: 2.49B

Mangalam Drugs and Organics Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Mangalam Drugs and Organics Ltd EV/EBITDA ratio is currently 6.20, a key metric in Mangalam Drugs and Organics Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 6.20
• 2023: 16.07
• 2022: 9.23
• 2021: 5.43

Stable Mangalam Drugs and Organics Ltd EV/EBITDA indicates balanced valuation.

Mangalam Drugs and Organics Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Mangalam Drugs and Organics Ltd D/E ratio is currently 0.64, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.64
• 2023: 0.79
• 2022: 0.58
• 2021: 0.58

Mangalam Drugs and Organics Ltd maintains moderate leverage with manageable risk.

Return on Equity (ROE %)

The Mangalam Drugs and Organics Ltd ROE currently stands at 4.72%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 4.72
• 2023: -6.31
• 2022: 0.84
• 2021: 13.97

Declining ROE indicates pressure on profitability.

Mangalam Drugs and Organics Ltd Ratios Analysis Summary

The Mangalam Drugs and Organics Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Mangalam Drugs and Organics Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Mangalam Drugs and Organics Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.